Back to discover
Drug

Pneumococcal Vaccines

In clinical development
Emerging researchLate-stage developmentRising momentum

Also known as pneumococcal vaccine, unspecified formulation, pneumococcal, unspecified formulation, PNEUMOCOCCAL VACCINE.

RxNorm106467
4
Research papers
5
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes

Clinical trial2026-07-09Results expected Q1 2027 · ClinicalTrials.gov

Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients Aged 45-80 Years: A Multicenter, Open-Label, Blank-Controlled Clinical Trial

Clinical trial2026-06-11Results expected Q2 2027 · ClinicalTrials.gov

A Structured Health Assessment in Frequent COPD Exacerbators: To Optimise Management, Identify Comorbidities and Prevent Oral Corticosteroid Related Harm

Clinical trial2026-04-23Results expected Q1 2029 · ClinicalTrials.gov

Effect of Methotrexate Discontinuation on Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Patients With Autoimmune Rheumatic Diseases

Clinical trial2026-03-24Results expected Q4 2027 · ClinicalTrials.gov

Safety and Immunogenicity of the 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Children and Adolescents With Autoimmune Rheumatic Diseases

Clinical trial2026-03-04Results expected Q4 2026 · ClinicalTrials.gov

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Clinical trial2025-03-03Results posted · ClinicalTrials.gov

Optimisation of Lymph Node Fine Needle Aspiration to Study Pneumococcal Vaccine-induced Immunity

Clinical trial2024-10-15Primary completion · ClinicalTrials.gov

Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.

Research2024-09-27Nature communications

Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.

Research2024-02-01The Lancet. Infectious diseases

COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age

Clinical trial2023-09-28Results posted · ClinicalTrials.gov

Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency.

Research2020-11-04Scientific reports

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Research2013-09-24PLoS medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Pneumococcal Vaccines
Aliases & brands
pneumococcal vaccine, unspecified formulationpneumococcal, unspecified formulationPNEUMOCOCCAL VACCINE
RxNorm CUI
106467

Clinical trials

18 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
18
registered trials across all phases
LATEST COMPLETION 2023
5
Active studies
5
Recruiting
10
Late-stage (III+)
11
Completed
2
Discontinued
PHASE DISTRIBUTIONn = 18
Phase 12Phase 1 / 21Phase 25Phase 33Phase 45Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Effect of Methotrexate Discontinuation on Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Patients With Autoimmune Rheumatic Diseases

Not yet recruitingPH IVUniversity of Sao Paulo General Hospitaln=1922028

Health Economic Evaluation of Influenza and Pneumococcal Vaccination in COPD Patients Aged 45-80 Years: A Multicenter, Open-Label, Blank-Controlled Clinical Trial

Not yet recruitingPH IVKey trialJiangsu Province Centers for Disease Control and Preventionn=7,0002027

Safety and Immunogenicity of the 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Children and Adolescents With Autoimmune Rheumatic Diseases

RecruitingPH IVUniversity of Sao Paulo General Hospitaln=1142027

Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes

RecruitingPH IVUniversity of Alabama at Birminghamn=702027

Immunogenicity of Pneumococcal Vaccination and Revaccination in Older Adults

CompletedPH IVNational Institute on Aging (NIA)n=1002012

Recent completions

Trials that read out recently, adding to the completed evidence base.

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

CompletedPH IIIKey trialSanofi Pasteur, a Sanofi Companyn=1,6602023

COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age

CompletedPH IICureVacn=6682022

Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico

CompletedPH IIISanofi Pasteur, a Sanofi Companyn=7202014

Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh

CompletedPH ISanofi Pasteur, a Sanofi Companyn=2802013

Immunogenicity of Pneumococcal Vaccination and Revaccination in Older Adults

CompletedPH IVNational Institute on Aging (NIA)n=1002012

Immuno-Augmentation With GM-CSF in Patients Receiving Pneumococcal Vaccine While Undergoing Treatment for Advanced Chronic Lymphocytic Leukemia (CLL)

CompletedPH IIM.D. Anderson Cancer Centern=392011

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20132024
Most influential

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

PLoS medicine · 2013 · 349 cites

Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency.

Scientific reports · 2020 · 135 cites

Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.

The Lancet. Infectious diseases · 2024 · 86 cites

Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.

Nature communications · 2024 · 13 cites
Recent papers

Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.

The Lancet. Infectious diseases · 2024 · 86 cites

Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.

Nature communications · 2024 · 13 cites

Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency.

Scientific reports · 2020 · 135 cites

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

PLoS medicine · 2013 · 349 cites
Major research themes6
Pneumococcal Infections2Pneumococcal Vaccines2Streptococcus pneumoniae2Immunization Schedule1Population Surveillance1Vaccines, Conjugate1
Journals, researchers & institutions
Top journals
  • Nature communications1
  • PLoS medicine1
  • Scientific reports1
  • The Lancet. Infectious diseases1
Leading researchers
  • Abdullahi F1
  • Anderson RM1
  • Andrews NJ1
  • Bentley SD1
  • Bertran M1
  • Cherian T1
  • Chochua S1
  • Cohen C1
Leading institutions
free-text, unnormalised
  • School of Public Health2
  • Centers for Disease Control and Prevention1
  • Centre for Respiratory Diseases and Meningitis1
  • Johns Hopkins Bloomberg School of Public Health1
  • London School of Hygiene & Tropical Medicine1
  • Milner Centre for Evolution1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas
Pneumococcal Infections4

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Erythromycin

Studied across the same disease area as Pneumococcal Vaccines in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials